A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability and Pharmacokinetics of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 May 2017
At a glance
- Drugs UCB 7858 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors UCB
- 14 Oct 2016 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017.
- 14 Oct 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017.
- 13 Sep 2016 New trial record